FTC Wants Martin Shkreli Held in Contempt for Trading Pharma Stocks
FROM THE WIRE · SEEKINGALPHA.COM
[Jury Deliberations Continue In Martin Shkreli Securities Fraud Trial] The Federal Trade Commission has asked a federal judge to hold in contempt the former CEO of Retrophin and Turing Pharmaceuticals (now renamed Vyera Pharmaceuticals), Martin Shkreli, for allegedly violating a…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishA legal proceeding against an individual for court order violation has limited impact on the pharma sector overall.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01FTC asked a federal judge to hold Shkreli in contempt of court.
- 02Shkreli allegedly violated a 2022 order banning him from the pharmaceutical industry.
- 03He reportedly traded in at least 60 pharma stocks and posted opinions on social media.
NEWS IMPACT AND MARKET REACTIONChange from the reference price
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets